Shares of Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) gapped up before the market opened on Thursday . The stock had previously closed at $15.23, but opened at $15.25. Lexicon Pharmaceuticals shares last traded at $15.53, with a volume of 175,854 shares changing hands.

A number of analysts have weighed in on the stock. Cowen and Company reissued a “market perform” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, May 3rd. JPMorgan Chase & Co. restated a “hold” rating and set a $16.00 price target on shares of Lexicon Pharmaceuticals in a report on Thursday, May 5th. Needham & Company LLC restated a “buy” rating and set a $21.00 price target on shares of Lexicon Pharmaceuticals in a report on Wednesday, May 4th. Zacks Investment Research cut Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, May 6th. Finally, Wedbush restated an “outperform” rating and set a $28.00 price target (down from $30.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, May 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $18.50.

The stock has a 50-day moving average price of $14.39 and a 200 day moving average price of $12.35. The stock’s market cap is $1.64 billion.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by $0.04. The company earned $12.50 million during the quarter, compared to the consensus estimate of $11.11 million. Lexicon Pharmaceuticals’s revenue was up 594.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.04) EPS. On average, equities analysts predict that Lexicon Pharmaceuticals Inc. will post ($1.55) earnings per share for the current year.

In related news, VP James F. Tessmer sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, May 23rd. The stock was sold at an average price of $13.00, for a total value of $78,000.00. Following the completion of the sale, the vice president now owns 21,946 shares in the company, valued at approximately $285,298. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

A number of institutional investors recently made changes to their positions in LXRX. California State Teachers Retirement System boosted its position in shares of Lexicon Pharmaceuticals by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 76,947 shares of the biopharmaceutical company’s stock worth $1,024,000 after buying an additional 1,372 shares during the period. ProShare Advisors LLC boosted its position in shares of Lexicon Pharmaceuticals by 7.7% in the fourth quarter. ProShare Advisors LLC now owns 89,382 shares of the biopharmaceutical company’s stock worth $1,190,000 after buying an additional 6,390 shares during the period. Nationwide Fund Advisors boosted its position in shares of Lexicon Pharmaceuticals by 124.1% in the fourth quarter. Nationwide Fund Advisors now owns 139,876 shares of the biopharmaceutical company’s stock worth $1,862,000 after buying an additional 77,446 shares during the period. Finally, New York State Common Retirement Fund boosted its position in shares of Lexicon Pharmaceuticals by 240.2% in the fourth quarter. New York State Common Retirement Fund now owns 177,168 shares of the biopharmaceutical company’s stock worth $2,358,000 after buying an additional 125,083 shares during the period.

Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.